Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Departments of Neurology and Ophthalmology, Mayo Clinic, Rochester, MN, USA.
Mult Scler. 2023 May;29(6):748-752. doi: 10.1177/13524585221150743. Epub 2023 Jan 24.
Data on corpus callosum involvement in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited.
The objective of the study was to compare callosal lesions in MOGAD, multiple sclerosis (MS), and aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD).
Callosal lesion frequency was similar in MOGAD (38/171 (22%)), MS (24/72 (33%)), and AQP4+NMOSD (18/63 (29%)). Clinical phenotypes included encephalopathy (47%) and focal supratentorial (21%) or infratentorial (45%) deficits. None had callosal-disconnection syndromes. Maximal callosal-T2-lesion diameter (median (range)) in millimeter was similar in MOGAD (21 (4-77)) and AQP4+NMOSD (22 (5-49); = 0.93) but greater than in MS (10.5 (2-64)). Extracallosal extension (21/38 (55%)) and T2-lesion resolution (19/34 (56%)) favored MOGAD.
Despite similar frequency and imaging overlap, larger lesions, sagittal midline involvement, and lesion resolution favored MOGAD.
关于胼胝体受累在髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）中的数据有限。
本研究旨在比较 MOGAD、多发性硬化症（MS）和水通道蛋白 4-IgG 阳性视神经脊髓炎谱系障碍（AQP4+NMOSD）患者的胼胝体病变。
MOGAD（38/171[22%]）、MS（24/72[33%]）和 AQP4+NMOSD（18/63[29%]）的胼胝体病变频率相似。临床表型包括脑病（47%）和局灶性幕上（21%）或幕下（45%）缺损。均无胼胝体切断综合征。胼胝体 T2 病变最大直径（中位数（范围））在毫米方面，MOGAD（21（4-77））和 AQP4+NMOSD（22（5-49）； = 0.93）相似，但大于 MS（10.5（2-64））。胼胝体外扩展（21/38[55%]）和 T2 病变消退（19/34[56%]）有利于 MOGAD。
尽管病变频率和影像学重叠相似，但更大的病变、矢状中线受累和病变消退更有利于 MOGAD。
